There are currently 233 ongoing clinical trials involving Sepsis
Of the 233 trials,80 trials are in Phase II
Furthermore, 52 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Sepsis, an infectious Disease. The largest number of ongoing clinical trials for Sepsis is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Sepsis-related drug trials.
Sepsis related clinical trial sponsor
Indian Council of Medical Research, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanghai Jiao Tong University School of Medicine, Assistance Publique - Hopitaux de Paris, Rigshospitalet, and Hartford Hospital are among other notable clinical trial sponsors involved in Sepsis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Sepsis
Amoxicillin and Clavulanate potassium (Augmentin, Augmentin Trio forte, Clavulin, Augmentin Duo, Augmentin ES, Clavamox, Augmentin Forte, Augmentin Duo Forte, Agumentin P), Cefoperazone Sodium and Sulbactam sodium (Sulperazone, Magnex, Magnex Forte), and Pneumococcal polysaccharide [10-valent] vaccine (Synflorix) are among the key marketed drugs involving Sepsis.
Amoxicillin and Clavulanate potassium (Augmentin, Augmentin Trio forte, Clavulin, Augmentin Duo, Augmentin ES, Clavamox, Augmentin Forte, Augmentin Duo Forte, Agumentin P ) is fixed dose combination drug, is an antibacterial agent. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as tablet, film coated tablets, chewable tablets, powder for suspension and powder for solution for oral route of administration and powder for solution for intravenous route of administration. Amoxicillin and Clavulanate potassium is marketed for the treatment of Sepsis and several other indications including Urinary Tract Infections, Respiratory Tract Infections, Bacillary Dysentery (Shigellosis), Acute Bronchitis, Bacterial Pneumonia, Pharyngitis, Gonorrhea, Laryngitis, Abscess, Bacteremia, Cellulitis, Upper Respiratory Tract Infections, Chronic Bronchitis, Lower Respiratory Tract Infections, Community Acquired Pneumonia, Urethritis, Otitis Media, Tonsillitis, and Bronchitis. Amoxicillin and Clavulanate potassium was first approved in 1982 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including GlaxoSmithKline Plc, and NeoPharma Inc.
Cefoperazone Sodium and Sulbactam sodium (Sulperazone, Magnex, Magnex Forte) is a fixed combination of cephalosporin antibiotic and beta-lactamase inhibitor. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as injectable powder for solution for intravenous route of administration. Cefoperazone Sodium and Sulbactam sodium is marketed for the treatment of Sepsis and several other indications including Urinary Tract Infections, Bacterial Conjunctivitis, Cholangitis, Cholecystitis, Pancreatitis, Acute Bronchitis, Bacterial Pneumonia, Pharyngitis, Gonorrhea, Bacterial (Pyogenic) Meningitis, Laryngitis, Abdominal Abscess, Abscess, Liver Abscess, Endometriosis, Tonsillitis, Acute Bacterial Sinusitis, Adnexitis, and Bacterial Endocarditis. Cefoperazone Sodium and Sulbactam sodium was first approved in 1986 and is marketed globally including China, India, Indonesia, and Japan by Pfizer Inc and its subsidiaries.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer